Sökning: "neutropenia"
Visar resultat 16 - 20 av 37 avhandlingar innehållade ordet neutropenia.
16. Regulation and characterization of antimicrobial peptides in man and mice
Sammanfattning : The gene-encoded antimicrobial peptides have emerged as an important component of innate immunity. In mammals, antimicrobial peptides are either directly secreted from cells or found in cell granules, which can be released after stimuli. LÄS MER
17. Bloodstream infections in patients with hematological malignancies
Sammanfattning : Patients with hematological malignancies have an increased risk of infectious complications. These complications can be caused by disease-specific factors or be treatment-related. Bloodstream infections increase the risk of morbidity, mortality, have a negative impact on quality of life, and may lead to reductions in treatment intensity. LÄS MER
18. Identification of Candidate Genes in Four Human Disorders
Sammanfattning : The aim of this thesis has been to identify genes and gene regions underlying four different disorders. In papers I-IV, positional cloning methods, such as linkage, association and haplotype analysis have been used for the identification of genomic regions associated with the ichthyosis prematurity syndrome (IPS), adult-onset autosomal dominant leukodystrophy (ADLD) and Kostmann disease. LÄS MER
19. Antibiotics in patients on chemotherapy; aspects on pharmacokinetic and pharmacodynamic interactions with antineoplastic drugs
Sammanfattning : The aims of these studies were to investigate the pharmacokinetics of two beta-lactam antibiotics in patients with fever and cytostatic-induced neutropenia and the influence of cytostatic-induced gastrointestinal damage on the absorption of co-trimoxazole. Furthermore to study the pharmacodynamic interactions between antibiotics and antineoplastic drugs and the impact of antineoplastic drugs on the intestinal microflora. LÄS MER
20. Mechanism-Based Pharmacokinetic and Pharmacodynamic Modelling of Paclitaxel
Sammanfattning : Paclitaxel (Taxol®) is now widely used against breast, ovarian and non-small-cell lung cancer. Anticancer agents generally have narrow therapeutic indices, often with myelosuppression (mainly neutropenia) as dose-limiting side effect. LÄS MER